A retrospective study of flow cytometric characterization of suspected extranodal lymphomas in dogs by V. Martini et al.
Page 1 of 24 
A retrospective study of flow cytometric characterization of suspected extranodal 1 
lymphomas in dogs 2 
 3 
Valeria Martini,1 Maverick Melega, Fulvio Riondato, Laura Marconato, Marzia Cozzi, Serena 4 
Bernardi, Stefano Comazzi, Luca Aresu 5 
 6 
Department of Veterinary Medicine, University of Milan, Milan, Italy (Martini, Cozzi, Bernardi, 7 
Comazzi); Department of Veterinary Sciences, University of Turin, Grugliasco, Turin, Italy 8 
(Melega, Riondato, Aresu); Centro Oncologico Veterinario, Sasso Marconi, Bologna, Italy 9 
(Marconato). 10 
 11 
1Corresponding author: Valeria Martini, Department of Veterinary Medicine, University of 12 
Milan, Via Celoria 10, 20133, Milan, Italy. valeria.martini@unimi.it 13 
 14 
Running title Flow cytometric assessment of canine extranodal lymphomas 15 
16 
Page 2 of 24 
Abstract. Flow cytometry (FC) is widely applied to characterize and stage nodal lymphomas in 17 
dogs because it has a short turnaround time, requires minimally invasive sampling, and allows 18 
contemporary evaluation of neoplastic cells in the primary lesion and of blood and marrow 19 
involvement. We investigated advantages and limitations of FC in suspected extranodal 20 
lymphomas in dogs. The likelihood of obtaining a suitable FC sample was significantly lower for 21 
aspirates of extranodal lesions than for lymph node aspirates. However, we noted no differences 22 
among different extranodal lesion sites. We also describe FC results for 39 samples compatible 23 
with extranodal lymphoma. A dominant population of large cells was easily identified on 24 
morphologic FC scattergrams in many cases. Phenotypic aberrancies were frequently present, 25 
mainly in T-cell lymphomas. Lymphoma cells were distinguishable from normal residual 26 
lymphocytes in >85% of cases, facilitating the quantification of putative blood and marrow 27 
involvement by FC. Despite the high percentage of non-diagnostic samples (32 of 73, >40%), we 28 
support the inclusion of FC in the diagnostic workup of suspected extranodal lymphomas in 29 
dogs, in conjunction with histopathology. Histopathology is the gold standard for diagnosing 30 
lymphoma, provides relevant information, including tissue invasion and epitheliotropism, but has 31 
a longer turnaround time. 32 
 33 
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Introduction 36 
Diagnostic flow cytometry (FC) was introduced in veterinary medicine at the end of the 20th 37 
century35; the primary use of FC is in characterizing canine hematopoietic neoplasms.6,27 FC 38 
provides useful information in dogs with lymphoma, including phenotype of neoplastic cells,12 39 
lymphoma subtype,36 expression of specific markers,25,26 stage,20,21,28,29 and presence of minimal 40 
residual disease.1 41 
Most FC studies in dogs have focused on nodal lymphoma; only a few reports have 42 
characterized primary extranodal lymphomas.9,11,15,31 Conversely, in human medicine, FC is 43 
routinely included in the diagnostic workup of extranodal lymphomas.3,19,32,34,37,38 In addition, 44 
FC is a safe and minimally invasive technique to confirm the diagnosis of lymphoma in cats, a 45 
species with a high prevalence of extranodal forms.14,23 46 
Given these premises, the aim of our retrospective study was to describe FC results in a 47 
case series of suspected canine extranodal lymphomas. We initially questioned whether the 48 
likelihood of obtaining a diagnostic sample varied between nodal and extranodal forms, and 49 
among different extranodal sites. Then, we describe the FC features of a series of cases 50 
compatible with extranodal lymphomas, including detailed phenotype and putative tumor burden 51 
in blood and bone marrow quantified by FC. For this second aim, we added cases obtained from 52 
a second FC database in order to consolidate the dataset. 53 
Materials and methods 54 
Case selection 55 
To assess the likelihood of obtaining diagnostic samples, the FC database of the Department of 56 
Veterinary Medicine, University of Milan (Milan, Italy) was examined retrospectively from 57 
January 2009 to September 2017, and canine cases were extracted. Cases were included if FC 58 
immunophenotyping was requested for a fine-needle aspirate obtained from lesions suspected to 59 
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be lymphoma at extranodal sites, excluding effusions and lymphoid organs (thymus, spleen, and 60 
tonsils). Cases were subsequently excluded if generalized lymphadenopathy was identified or if 61 
the nodal status was not reported. For each case, lesion site and FC results were retrieved. 62 
FC results were considered consistent with lymphoma if cases fulfilled the following 63 
criteria: 1) cytologic evaluation performed prior to FC was compatible or suggestive of round-64 
cell neoplasia, likely of lymphoid origin; 2) well-preserved FC sample, with minimal debris and 65 
disrupted cells and minimal hemocontamination; and 3) presence of a dominant lymphoid 66 
population sharing a unique morphologic and phenotypic pattern.5 Hepatic samples were 67 
diagnosed as lymphoma only if infiltrating leukemia was unambiguously ruled out. Acute 68 
leukemia was suspected if CD34+ cells were detected, whereas chronic lymphocytic leukemia 69 
(CLL) was included in the differential if neoplastic cells had a mature morphologic appearance, 70 
were small, CD34–, and CD21+, CD4+, or CD8+ on FC. One dog had a proliferation of small 71 
mature CD4+ lymphocytes in the liver and was retained in the study. CLL was excluded in this 72 
dog based on the following: slight peripheral blood (PB) lymphocytosis, mild enlargement of 73 
hepatic lymph nodes (LNs) with all other LNs within normal limits, and/or death from 74 
progressive disease within 15 d of the diagnosis, despite corticosteroid therapy. 75 
Control canine cases consisted of suspected nodal lymphomas cases extracted from the 76 
same FC database, according to the following inclusion criteria: 1) generalized 77 
lymphadenopathy; 2) no extranodal lesions; and 3) LN aspirate sent to the laboratory for FC. 78 
In a second step, to consolidate the dataset of samples with FC results compatible with 79 
extranodal lymphomas, additional cases were included from the FC database of the Veterinary 80 
Teaching Hospital, University of Turin (Grugliasco, Italy). For all cases included in this dataset, 81 
the referring veterinarians were contacted to retrieve follow-up data. 82 
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All of the dogs were privately owned and sampled for diagnostic purposes with the 83 
informed consent of the owners. Thus, specific formal approval by the authors’ Institution 84 
Committee for Animal Care was not required (protocol 1965-2017, Ethical Committee, 85 
University of Turin). 86 
Flow cytometry 87 
FC was performed on tissue aspirates collected in tubes containing 1 mL of a liquid medium 88 
(either RPMI-1640 or saline solution). Prior to labeling, sample cellularity was assessed with an 89 
automated hematology analyzer (XT-2000iV, Sysmex, Kobe, Japan; or ADVIA 120, Siemens 90 
Healthcare Diagnostics, Milan, Italy). Also, a visual inspection was done by the operator, in 91 
order to assess the gross quality of the sample and decide whether to perform FC labeling.23 92 
Processing for FC was performed as described previously,12 using different combinations 93 
of antibodies (Table 1), with a multicolor approach. For intracellular staining, a permeabilization 94 
procedure was performed using either Leucoperm reagents (Serotec, Oxford, UK) following the 95 
manufacturer’s instructions, or FACS permeabilizing solution 2 (Becton Dickinson, San Josè, 96 
CA) as described.12 Samples were acquired with a FACSCalibur or a Accuri C6 flow cytometer 97 
(Becton Dickinson) and analyzed with Cell Quest or CFlow Plus software (Becton Dickinson). 98 
Cells were classified as “small” when showing the same FC morphologic properties 99 
(forward-scatter [FSC] and side-scatter [SSC]) of residual normal lymphocytes, and as “large” 100 
when 2 distinct lymphoid populations were identifiable based on FSC and SSC (normal small 101 
lymphocytes and large neoplastic cells). Cases compatible with lymphoma were classified as B 102 
cell if cells from the dominant population expressed CD21, CD79a, or CD79b, and did not 103 
express any T-cell marker. T-cell lymphomas were identified when cells expressed CD3, CD5, 104 
CD4, CD8, or CycD3, and did not express any B-cell marker. Cases were classified as T cell 105 
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when the dominant population expressed concomitantly any T-cell marker and CD21 but not 106 
CD45.22 107 
When available, PB and/or bone marrow (BM) samples collected into EDTA tubes were 108 
also analyzed by FC to quantify the infiltration by putative neoplastic cells. Red blood cells were 109 
lysed prior to labeling by means of an erythrocyte lysis buffer containing 8% ammonium 110 
chloride. Putative infiltration degree was defined as the percentage of nucleated cells showing 111 
the same FC morphologic and phenotypic characteristics of the dominant population identified in 112 
the tissue aspirate. 113 
Statistical analysis 114 
For statistical analysis, extranodal lesions were grouped into skin, liver, head and neck, and other 115 
sites. Contingency tables were prepared, and the Pearson chi-square test was performed to assess 116 
possible different likelihoods of obtaining a sample suitable for FC assessment by comparing 117 
nodal and extranodal samples, and extranodal samples among different sites. Analyses were then 118 
performed (Statistics v.20.0, SPSS, Chicago, IL). Significance was set at p ≤ 0.05. 119 
Results 120 
Diagnostic yield of nodal and extranodal samples from different sites 121 
Seventy-three canine extranodal samples were retrieved from the FC database of the Department 122 
of Veterinary Medicine (Milan). Poor cellularity, excessive hemodilution, and high content of 123 
debris and disrupted cells were the principal limitations affecting the quality of the samples and 124 
the suitability for FC assessment. Lesions were located in the skin in 33 cases (45%), liver in 13 125 
(18%), head and neck in 8 (11%), and elsewhere in 19 (26%), including kidney (n = 5), 126 
cerebrospinal fluid (n = 4), bowel (n = 2), lung (n = 2), and 1 each of the following: anal sac, 127 
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joint, pancreas, stomach, peritoneum, and adrenal gland. Forty-one samples (56%) were 128 
considered suitable for FC assessment. 129 
Considering only the acceptable samples, FC results were compatible with histiocytic 130 
proliferative disease in 3 cases (7%), and 1 case (2%) was suspect for infiltration by CLL 131 
because a unique population of small mature CD8+ lymphocytes was identified invading liver 132 
and bone marrow. A mixed population of small lymphocytes was present in 9 cases (22%), with 133 
large cells accounting for <5% of the population in all instances; because none of the lymphoid 134 
population was dominant, these samples were considered negative for hematopoietic neoplasia. 135 
In the remaining 28 (68%) cases, a dominant cell population was identifiable; these samples 136 
were considered consistent with extranodal lymphoma (Table 2). 137 
The control population consisted of 894 dogs in which nodal lymphoma was suspected. A 138 
total of 820 cases (92%) were suitable for FC assessment, and 743 cases (91%) were consistent 139 
with lymphoma (Table 2). 140 
The proportion of samples suitable for FC assessment varied significantly between 141 
extranodal and nodal samples (p < 0.001), with the latter being more likely acceptable (odds 142 
ratio: 8.64; 95% confidence interval: 5.14–14.5). The difference was not significant among 143 
different extranodal sites (p > 0.05). 144 
FC features of extranodal lymphomas 145 
To consolidate the dataset, 11 additional samples consistent with extranodal lymphoma obtained 146 
from the Veterinary Teaching Hospital (Turin) were included. Thus, the FC features of 39 cases 147 
were described (Table 3). The skin was involved in 16 (41%) dogs, the liver in 9 (23%), and the 148 
head and neck in 5 (13%). The remaining 9 (23%) cases involved kidneys (n = 3), bowel (n = 2), 149 
and 1 each in urinary bladder, tibia, lung, and peritoneum. A round cell tumor was suspected in 150 
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all cases based on cytologic examination performed prior to FC; histopathology and 151 
immunohistochemistry were performed in 9 cases, with a diagnosis of lymphoma. 152 
A dominant population of cells was easily identified based on morphologic features (large 153 
cells) in 25 (64%) cases. Phenotypic aberrancies were commonly found in T-cell lymphomas (20 154 
cases, 80%), including lack of expression of both CD4 and CD8, discordant expression of pan–155 
T-cell markers, expression of CD8 but not of CD3 or CD5, lack of expression of CD45, and 156 
expression of CD21. In particular, 10 (50%) of these cases had more than 1 phenotypic 157 
aberrancy. Among suspected B-cell lymphomas, only 1 case (7%) was CD21–CD79+. 158 
Interestingly, KIT expression was detected in 2 B-cell lymphomas (14%). In 5 (13%) cases, the 159 
dominant population was cells with FC properties overlapping those of normal small 160 
lymphocytes; the dominant cells were also small and showed no phenotypic aberrancies, with the 161 
exception of KIT expression in 1 dog. 162 
Concerning phenotype distribution, the skin was more commonly affected by 163 
proliferation of CD45+CD4–CD8– T cells (n = 7, 44%), the liver by B cells (n = 5, 56%), and 164 
the head and neck by CD45– T-cell lymphomas (n = 3, 60%). B-cell proliferation was more 165 
common in the miscellaneous group (n = 5, 56%). 166 
PB and BM samples were available for FC analysis in 25 and 22 cases, respectively. 167 
Putative neoplastic lymphoid cells were present in 15 (60%) PB samples, with a mean infiltration 168 
level of 20 ± 24% (median: 8%, min.–max.: 1–79%) and in 9 (41%) BM samples, with a mean 169 
infiltration level of 14 ± 17% (median: 4%, min.–max.: 1–37%). 170 
Follow-up data were retrieved for 14 dogs. Lesions involved the skin in 8 cases; head and 171 
neck in 3; liver, bowel, and kidney in 1 each. Ten (71%) dogs were treated with corticosteroids 172 
or different chemotherapy protocols and died because of progressive disease, with a median 173 
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survival of 77 d (range: 15–249 d). Two (14%) dogs with cutaneous lymphoma were treated with 174 
multi-agent chemotherapy obtaining partial and complete remission and died as a result of 175 
lymphoma-unrelated causes after 113 and 603 d, respectively. Two (14%) dogs with tongue 176 
lesions received chemotherapy and obtained complete clinical remission; one was still alive after 177 
579 d, the second one died because of lymphoma-unrelated causes after 427 d. 178 
Discussion 179 
Approximately half of the suspected extranodal lymphomas included in our study had an intra-180 
abdominal location, and most of them involved the liver, which caused the dominant health issue 181 
in these dogs. This was unexpected, considering the low frequency reported in the literature for 182 
this lymphoma presentation in dogs.16 Conversely, cutaneous lymphomas are common, with the 183 
epitheliotropic subtype alone accounting for 3–8% of all canine lymphomas.4 This result can be 184 
explained by the preferential use of less invasive sampling when intra-abdominal lesions are 185 
present, whereas the skin is more likely to be biopsied. Nevertheless, the presence of mild 186 
peripheral lymphadenomegaly may have gone unnoticed by the clinicians in some cases, thereby 187 
raising the number of dogs with suspected primary hepatic lymphoma. 188 
The phenotypes of the dominant cell population identified by FC in our study showed a 189 
different distribution between nodal and extranodal samples. As described previously, B cell is 190 
the most common phenotype in nodal lymphomas,2,36 and CD4+ phenotype is the most frequent 191 
in multicentric T-cell lymphomas.9 Cutaneous lymphomas are more frequently composed of 192 
CD4– T cells with variable expression of CD8,4,24 whereas cutaneous B-cell lymphomas are less 193 
common.7,8 194 
Interestingly, the prevalence of a CD45– T-cell phenotype did not vary between nodal 195 
and suspected extranodal lymphomas. This phenotype is considered highly suggestive of T-zone 196 
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lymphoma (TZL) in dogs.22,30,33 Three of 4 CD45– T-cell extranodal lymphomas in our case 197 
series were located within the oral cavity, and 2 of them involved the tongue. This has been 198 
described as a novel presentation of canine TZL.15 The remaining CD45– T-cell lymphoma was 199 
a peritoneal mass near the spleen. The neoplastic cells in the mass were large based on the FC 200 
morphologic scattergram, and expressed CD3 and CD8. Unfortunately, CD5 and CD21 201 
expression was not tested, and cytologic specimens were not available for review. Because cells 202 
were large, it is likely that the final diagnosis in this case was peripheral T-cell lymphoma rather 203 
than TZL. 204 
We found that <60% of submitted extranodal samples were suitable for FC assessment, 205 
which is considerably lower than the results obtained for nodal samples (>90%). Several 206 
possibilities might explain this difference, including discomfort in the sampling procedure given 207 
the intra-abdominal location of the lesions, different size and characteristics of the lesion 208 
(extranodal tissue thickening vs. gross LN enlargement), different cellular exfoliation from 209 
tissues other than nodes, and higher content of debris and parenchymal cells in the extranodal 210 
lesions. Further, a greater variety of lesions can affect extranodal sites compared to LN, which is 211 
confirmed by the relatively high frequency (>20%) of non-hematopoietic tumors that were 212 
encountered among extranodal samples. Finally, other pre-analytical factors may have influenced 213 
the diagnostic yield of the samples, as has been demonstrated in canine LNs5 and nodal and 214 
extranodal lesions in cats.23 Regardless of the underlying causes, the risk of obtaining samples 215 
not suitable for FC assessment should be taken into account in the diagnostic workup of 216 
extranodal lesions. 217 
Phenotypic aberrancies were commonly found in the cases consistent with extranodal 218 
lymphomas. Phenotypic aberrancies are defined as gross antigen deletions, expression of 219 
Page 11 of 24 
antigens that are not normally present on the cells, and co-expression or loss of both CD4 and 220 
CD8.18 In our case series, phenotypic aberrancies were detected in 20 (80%) samples consistent 221 
with T-cell lymphoma and in 1 (7%) consistent with B-cell lymphoma. Phenotypic aberrancies 222 
are generally more common in T-cell than B-cell nodal lymphomas,12 likely because a larger 223 
panel of T-cell antigens is tested routinely, allowing more detailed phenotypic definition. 224 
Conversely, only a few canine B-cell antigens can be tested by FC in dogs. CD79 labeling 225 
requires permeabilization, and is expensive, time-consuming, and is generally omitted if the cells 226 
of interest are CD21+. This approach further reduces the number of B-cell antigens tested. 227 
We recorded KIT expression in 2 cases. KIT expression has been investigated in canine 228 
nodal lymphomas,13 and the activity of masitinib, a tyrosine kinase inhibitor, has been 229 
documented in 10 dogs with epitheliotropic lymphoma, although none of them expressed KIT by 230 
immunohistochemistry.17 Further studies are needed to assess the possible clinical and 231 
therapeutic significance of KIT expression in canine extranodal lymphomas. 232 
We found high percentages of putative neoplastic cells in PB and BM of dogs with 233 
suspected extranodal lymphoma, which supports the utility of assessing infiltration of these 2 234 
tissues in extranodal lymphomas. We did not consider clinical and prognostic significance in our 235 
study. FC has optimal diagnostic performance in staging canine large B-cell lymphoma,28 but 236 
validation in other lymphoma subtypes is still lacking. However, large cells or phenotypic 237 
aberrancies are not present in PB from healthy dogs.10 Thus, we have confidence in the 238 
specificity of the results obtained for FC staging for most of the cases included in our study. A 239 
small subset of cases had a dominant population of small cells without phenotypic aberrancies in 240 
the primary extranodal lesion; thus, the cells with the same morphologic and phenotypic 241 
properties detected in PB and BM may represent either infiltrating neoplastic cells or 242 
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normal/reactive lymphocytes, or both. PCR for antigen receptor rearrangement would be 243 
informative in these cases. 244 
The retrospective nature of our study is a major limitation. Sampling procedures differed 245 
among veterinarians, influencing the diagnostic yield of cells. The antibody panel applied also 246 
varied in our dataset. In particular, the reduced number of cases tested for MHC II expression 247 
prevented us from deriving any information on this marker, which has been associated with a 248 
worse prognosis in dogs with nodal B-cell and CD4+ CD8– T-cell lymphomas if not 249 
expressed.9,26 Finally, histopathology was performed in only a small number of cases; therefore, 250 
we could not assess if FC features differed among different lymphoma histotypes. Further studies 251 
are needed to compare FC results and histologic diagnoses in a large case series, in order to 252 
assess the diagnostic utility of FC in discriminating lymphomas from non-neoplastic lymphoid 253 
lesions. 254 
FC can assist in the diagnostic workup in dogs with suspected extranodal lymphoma, 255 
despite the high percentage of non-diagnostic samples. Neoplastic cells may be distinguishable 256 
from normal residual lymphocytes by FC, facilitating staging procedures and quantification of 257 
infiltrating cells in PB and BM samples. We recommend the concomitant use of histopathology 258 
and FC. The advantages of FC are the short turnaround time (results are available the same day 259 
of sample delivery to the laboratory), the less invasive nature of sampling, and more 260 
comprehensive immunophenotyping; histopathology may provide a definitive diagnosis of 261 
lymphoma that includes architectural characterization and epitheliotropism of the neoplastic 262 
cells, but has a longer turnaround time. 263 
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Table 1. Antibodies used for flow cytometric immunophenotyping of suspected canine 358 
lymphoma samples. 359 
Target 
molecule 
Antibody 
clone Source Specificity 
CD45 YKIX716.13 Serotec, Oxford, UK All leukocytes 
CD3 CA17.2A12 Serotec T cells 
CD5 YKIX322.3 Serotec T cells  
CycD3 CD3-12 Serotec T cells 
CD4 YKIX302.9 Serotec T-helper cells and neutrophils 
CD8 YCATE55.9 Serotec T-cytotoxic cells 
CD21 CA2.1D6 Serotec Mature B cells 
CD79a HM57 Serotec B cells 
CD79b AT107-2 Serotec B cells 
CD34 1H6 BD Pharmingen, San Josè, CA Precursors  
MHC II YKIX334.2 Serotec Lymphocytes, monocytes 
CD117 ACK45 BD Pharmingen Precursors and mast cells 
 360 
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Table 2. Flow cytometric immunophenotype of 771 dogs with nodal or suspected extranodal lymphoma. 361 
 Lymphoma phenotype 
Total B cell 
T cell 
CD45+CD4+CD8– CD45+CD4–CD8+ CD45+CD4+CD8+ CD45+CD4–CD8– CD45– 
Nodal 550 (74) 82 (11) 21 (3) 5 (1) 22 (3) 63 (9) 743 (100) 
Extranodal 8 (29) 1 (4) 9 (32) 0 (0) 7 (25) 3 (11) 28 (100) 
Total 558 (72) 83 (11) 30 (4) 5 (1) 29 (4) 66 (9) 771 (100) 
Numbers in parentheses are percentages. 362 
363 
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Table 3. Flow cytometric features of the dominant lymphoid population in extranodal lesions compatible with lymphoma from 39 364 
dogs. 365 
Case 
ID Lesion site 
Cell 
size 
Dominant 
population 
(%) CD45 CD3 CD5 CD4 CD8 CD21 
CD79 (a 
or b) CD34 MHC II KIT CycD3 
PB 
lymphocyte 
count 
(×109/L) 
Putative 
infiltration 
(%) 
PB BM 
1 Skin Large 63 + + – – – – – ND ND ND ND 4.3 – – 
2* Skin Large 89 + – + – – – ND – ND – ND 1.1 – – 
3* Skin Small 69 + – + – – – ND ND ND ND ND 0.8 4 – 
4 Skin Small 98 + + + – – – ND ND ND – ND 7.6† 30 45 
5 Skin Large 80 + + – – – – ND – ND ND ND ND ND ND 
6 Skin Large 93 + + – – – – ND – + – ND ND ND ND 
7 Skin Large 70 + – – – – – – – + ND + ND ND ND 
8 Skin Small 87 + – – – + – ND ND ND – ND 1.2 – ND 
9* Skin Large 91 + + + – + – ND ND ND ND ND 0.7 5 1 
10 Skin Small 64 + ND + – + – ND ND ND ND ND ND ND ND 
11* Skin Large 87 + ND – – + – ND ND ND – ND 1.3 – – 
12* Skin Small 64 + ND – – + – ND ND ND ND ND 2.1 – – 
13 Skin Small 71 + – – – – + + – ND + ND 50.4† 30 ND 
14 Skin Small 81 + ND – – – + + – ND ND – 0.7 4 ND 
15 Skin Large 99 + ND – ND ND + ND – + ND ND ND ND ND 
16 Skin Large 99 + – – – – + ND – ND ND ND 1.7 2 3 
17 Liver Large 82 + ND – – – + ND – ND ND ND 85.2† 79 ND 
18 Liver Large 88 + ND ND – ND + ND – + ND ND 0.9 – ND 
19 Liver Large 81 + – – – – + + – ND ND ND 1.1 – – 
20 Liver Large 86 + ND – ND ND + ND – ND ND ND 1.9 1 2 
21 Liver Large 94 + – – – – + + – ND ND ND ND ND ND 
22 Liver Large 80 + + – – + ND ND – ND ND ND ND ND ND 
23 Liver Large 85 + – – – + – – ND ND ND ND 0.8 17 36 
24 Liver Small 76 + + + + – – ND – ND ND ND 6.2† 23 ND 
25 Liver Large 78 + – + – – – – – ND ND ND 1.5 – – 
26* Tongue Small 87 – + + + – + – – ND ND ND 7.9† 70 ND 
27 Tongue Small 78 – + + – + + ND – ND – ND 1.3 4 – 
28 Oral mucosa Small 64 – ND + ND ND – ND – ND ND ND 1.1 16 8 
29* Lip Small 97 + ND + – – – ND ND ND ND ND ND ND – 
30 Gum Small 70 + + + – + – ND – ND ND ND 2.3 2 2 
31 Kidney Large 89 + – – – – + + – ND + ND ND ND 28 
32 Kidney Large 96 + – – – – + + – ND ND – 1.5 – – 
33 Kidney Large 62 + ND – ND + – ND ND ND ND ND 2.2 – – 
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34* Bowel Large 97 + – ND ND ND + ND ND ND ND ND ND ND ND 
35 Bowel Large 66 + + – – – – – ND ND ND ND ND ND ND 
36 Urinary bladder Large 98 + ND ND ND ND + + – ND ND ND ND ND ND 
37 Tibia Small 65 + – – – – – + – ND – ND ND ND – 
38* Lung Large 97 + + – – + – ND – ND – ND ND ND – 
39 Peritoneum Large 86 – + ND ND + ND ND – ND ND ND 1.6 8 4 
– = negative; BM = bone marrow; ND = not done; PB = peripheral blood. 366 
* Histopathology performed. 367 
† Exceeding laboratory upper reference limit. 368 
